|
Earlier Antiretroviral Therapy
Might Reduce the Burden of Cancer in Those with HIV
Nov. 22, 2011 - OAKLAND, Calif., - HIV-infected patients are at increased risk for cancer as a result
of both their impaired immune system and lifestyle factors, such as smoking, according to researchers at Kaiser Permanente.
The study, which appears in the current issue of Cancer Epidemiology, Biomarkers and Prevention, is among the first to
directly compare the risk of cancer in HIV-infected patients with a comparison group without HIV infection, while accounting for
major cancer risk factors .
Of the 10 cancer types studied, six were more common in HIV patients, compared with patients without HIV infection - including,
Kaposi's sarcoma, non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma, anal cancer and liver cancer, while prostate cancer was less
common. Lung and oral-cavity cancers also occurred more frequently in HIV patients, although most of the risk appeared to be
due to risk factors such as smoking, according to the investigators.
Further analysis suggested that immunodeficiency - as measured by CD4 count (a measure of the strength of the immune system) - was
positively associated with the risk of all studied cancer types, except prostate cancer. The amount of HIV virus in the blood,
however, was only associated with two cancers, Kaposi's sarcoma and non-Hodgkin lymphoma, they said.
Most cancers found to be associated with immunodeficiency had a known infectious cause, suggesting a mechanism in which an impaired
immune system cannot adequately suppress certain cancer-causing viral infections such as human papillomavirus or hepatitis,
investigators explained . They also acknowledged that for some cancers, such as lung and oral-cavity cancers, the elevated
risk was multifactorial and likely resulted from both an impaired immune system and risk factors such as smoking.
"Taken together, we believe our results support cancer prevention strategies that combine routine prevention activities, such
as smoking cessation, with earlier HIV treatment to help maintain a patient's immune system," said study lead author
Dr. Michael Silverberg , PhD, MPH, a research scientist with the Kaiser Permanente Northern California Division of
Research. The main goal of the study, he added, was to determine how much of the increased cancer risk in HIV
patients resulted from their disease, and how much was due to risk factors. To accomplish this goal, they
performed a cohort study from 1996-2008 of adult HIV-infected and demographically similar HIV-uninfected
individuals from Kaiser Permanente Northern and Southern California . The risk for 10 cancer types were
compared between groups, while adjusting for cancer risk factors including smoking, alcohol/drug abuse,
and overweight/obesity. They also evaluated the effect of CD4 and HIV virus levels, both of which
are markers for HIV disease severity.
"After adjusting for risk factors, the incidence rates of six of 10 cancers were markedly elevated in HIV patients. When we
looked more closely we discovered that for most cancers studied - eight of 10 - HIV patients with the lowest CD4 had higher rates
compared with those without HIV," said Dr. Silverberg. "These findings need confirmation in other settings,
particularly colorectal cancer, which has not been previously linked to immunodeficiency."
Additional researchers on the study include: Chun Chao , PhD and Lanfang Xu , MS, with Kaiser Permanente Department of Research
& Evaluation in Pasadena, Calif. ; Wendy A. Leyden , MPH, Charles Quesenberry, Jr. , PhD, and Romain S. Neugebauer , PhD,
with Kaiser Permanente Northern California Division of Research; Michael Horberg , MD, with the Mid-Atlantic Permanente
Research Institute; William J. Towner , MD, with Kaiser Permanente Los Angeles Medical Center; Daniel Klein , MD,
with Kaiser Permanente Hayward Medical Center; Robert Dubrow , MD, PhD, with the Yale School of Public
Health ; and Donald I. Abrams , MD, with the University of California at San Francisco .
Funding was provided by grants from the National Institutes of Health, the Garfield Memorial Research Fund and Pfizer
Pharmaceuticals.
About the Kaiser Permanente Division of Research
( http://www.dor.kaiser.org/ )
The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health services research
to improve the health and medical care of Kaiser Permanente members and the society at large. It seeks to understand the
determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Currently,
DOR's 400-plus staff is working on more than 250 epidemiological and health services research projects.
About the Kaiser Permanente Department of Research & Evaluation
( http://www.kp-scalresearch.org )
The mission of the Department of Research & Evaluation is to initiate and conduct high-quality, public-sector health services,
epidemiologic, behavioral and clinical research that has a demonstrable positive impact on the health and well-being of Kaiser
Permanente Southern California members and the general population.
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health
care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care
services and to improve the health of our members and the communities we serve. We serve approximately 8.9 million members in
nine states and the District of Columbia . Care for members and patients is focused on their total health and guided by
their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and
supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the
art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations,
clinical research, health education and the support of community health. For more information, go
to: www.kp.org/newscenter .
For more information:
Danielle Cass , danielle.x.cass@kp.org , 510-267-5354
Maureen McInaney , maureen.mcInaney@kp.org , 510-987-4779
SOURCE: Kaiser Permanente
"Reproduced with permission - Kaiser Permanente"
Kaiser Permanente
|
